685 related articles for article (PubMed ID: 29229461)
1. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics.
Hegde PS; Wallin JJ; Mancao C
Semin Cancer Biol; 2018 Oct; 52(Pt 2):117-124. PubMed ID: 29229461
[TBL] [Abstract][Full Text] [Related]
2. A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy.
Kong DH; Kim MR; Jang JH; Na HJ; Lee S
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28817103
[TBL] [Abstract][Full Text] [Related]
3. Vaccination approach to anti-angiogenic treatment of cancer.
Wentink MQ; Huijbers EJ; de Gruijl TD; Verheul HM; Olsson AK; Griffioen AW
Biochim Biophys Acta; 2015 Apr; 1855(2):155-71. PubMed ID: 25641676
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan RR; Griffioen AW; Duda DG
Angiogenesis; 2017 May; 20(2):185-204. PubMed ID: 28361267
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
Front Immunol; 2020; 11():1956. PubMed ID: 32983126
[TBL] [Abstract][Full Text] [Related]
6. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.
Rosen LS
Cancer Control; 2002; 9(2 Suppl):36-44. PubMed ID: 11965229
[TBL] [Abstract][Full Text] [Related]
8. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Fukumura D; Kloepper J; Amoozgar Z; Duda DG; Jain RK
Nat Rev Clin Oncol; 2018 May; 15(5):325-340. PubMed ID: 29508855
[TBL] [Abstract][Full Text] [Related]
9. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
10. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.
Khan KA; Kerbel RS
Nat Rev Clin Oncol; 2018 May; 15(5):310-324. PubMed ID: 29434333
[TBL] [Abstract][Full Text] [Related]
11. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor as a therapeutic target in cancer.
Bergsland EK
Am J Health Syst Pharm; 2004 Nov; 61(21 Suppl 5):S4-11. PubMed ID: 15552621
[TBL] [Abstract][Full Text] [Related]
13. Is VEGF a predictive biomarker to anti-angiogenic therapy?
Otrock ZK; Hatoum HA; Musallam KM; Awada AH; Shamseddine AI
Crit Rev Oncol Hematol; 2011 Aug; 79(2):103-11. PubMed ID: 20724177
[TBL] [Abstract][Full Text] [Related]
14. Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response.
Geindreau M; Ghiringhelli F; Bruchard M
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34064508
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
Ferrara N; Hillan KJ; Novotny W
Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
[TBL] [Abstract][Full Text] [Related]
16. The Role of CC-Chemokines in the Regulation of Angiogenesis.
Ridiandries A; Tan JT; Bursill CA
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834814
[TBL] [Abstract][Full Text] [Related]
17. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
[TBL] [Abstract][Full Text] [Related]
18. Promising early results for immunotherapy-antiangiogenesis combination.
Garber K
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25421345
[No Abstract] [Full Text] [Related]
19. The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses.
Moens S; Goveia J; Stapor PC; Cantelmo AR; Carmeliet P
Cytokine Growth Factor Rev; 2014 Aug; 25(4):473-82. PubMed ID: 25169850
[TBL] [Abstract][Full Text] [Related]
20. Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy.
Patel SA; Nilsson MB; Le X; Cascone T; Jain RK; Heymach JV
Clin Cancer Res; 2023 Jan; 29(1):30-39. PubMed ID: 35969170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
